J. Čermák

Publications402
h-index33
Citations7,869
Highly Influential Citations335
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Fenaux
  • 1,523 Publications • 68,238 Citations
  • U. Germing
  • 800 Publications • 24,956 Citations
  • L. Malcovati
  • 362 Publications • 21,227 Citations
  • G. Garcia-Manero
  • 2,220 Publications • 70,509 Citations
  • Publications
  • Influence
Revised international prognostic scoring system for myelodysplastic syndromes.
TLDR
This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.
View on PubMed
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients…
TLDR
In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety, and an unplanned survival analysis showed a benefit for decit abine, which was not observed at the time of the primary analysis.
View on PubMed
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
TLDR
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program and Guidelines were developed on the basis of a list of patient- and therapy-oriented questions.
View on PubMed
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.
TLDR
C-reactive protein (CRP), an acute-phase reactant that markedly increases its serum concentration in response to inflammatory stimuli, induced monocytes to express tissue factor (TF), a potent procoagulant.
View on PubMed
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis
TLDR
The clinical course of refractory anemia with ring sideroblasts and marked thrombocytosis is better than that of refracted anemia without ring siders, and worse than those of essential thromBocythemia.
View on Publisher
Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
TLDR
CyA could offer an alternative treatment for certain MDS patients with RA regardless of hyper‐, normo‐ or hypo‐cellularity of bone marrow (BM), who were treated with cyclosporin A (CyA).
View on Wiley
BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.
TLDR
The study of 3 patients with rare microdeletions of 2p15-p16.1 who presented with an autism spectrum disorder and developmental delay and orthogonal genetic data demonstrates that BCL 11A plays a central role in silencing HbF in humans and implicates BCL11A as an important factor for neurodevelopment.
View on PubMed
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
TLDR
CC-486 maintenance therapy was associated with significantly longer overall and relapse-free survival than placebo among older patients with AML who were in remission after chemotherapy.
View on PubMed
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute…
TLDR
QUAZAR AML-001 (NCT01757535), a phase III international, randomized, double-blind, placebo (PBO)-controlled study evaluating CC-486 as maintenance therapy in pts aged ≥55 years with AML in first remission following IC, demonstrated significant improvements in OS and RFS.
View via Publisher
CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
View on PubMed
...
...